Skip to main content
TipRanks
Go Ultimate75% OFF

Natural Capsules Limited (NATCAPSUQ) AI Stock Analysis

0 Followers
IN:NATCAPSUQ

Natural Capsules Limited

(NSE:NATCAPSUQ)

Select Model
Rating:44Neutral
Price Target:INR 151.00â–²(4.35% Upside)
Action:reiterated
Date:10/29/26

The score is primarily constrained by deteriorating profitability and cash generation, with additional pressure from bearish technical momentum and a negative P/E ratio. A relatively solid balance sheet and strong revenue growth provide some support, but they do not yet offset the company’s losses and weak free cash flow.

Positive Factors
Revenue GrowthStrong FY2026 revenue growth shows that the company is expanding sales despite its profitability challenges. Continued top-line progress can provide operating scale and a broader base from which management may improve pricing, product mix, and cost absorption over the next several quarters.
Negative Factors
Sharp Profitability DeteriorationThe shift from near break-even performance to a sizable net loss indicates that revenue growth is not currently translating into shareholder earnings. Compressed gross margins and negative operating and EBITDA margins suggest substantial cost or mix pressure that could remain a material drag over coming quarters.

Natural Capsules Limited (NATCAPSUQ) vs. iShares MSCI India ETF (INDA)

-30%-20%-10%0%10%20%30%IN:NATCAPSUQ-19.83%INDA-5.34%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 1.45B
Dividend Yield
―
Average Volume (3M)
4,109
Price to Earnings (P/E)
-6.6
Beta (1Y)
0.35
Revenue Growth
8.84%
EPS Growth
-285.42%
Country
India
Employees
620
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Natural Capsules Limited Business Overview & Revenue Model

Company Description

Natural Capsules Ltd. specializes in the production and global distribution of hard gelatin and cellulose capsule shells, catering to markets in India and abroad. The company offers a comprehensive array of capsule types, including those guaranteed f...

Natural Capsules Limited Financial Statement Overview

Summary

Strong revenue growth is offset by sharply deteriorating profitability, negative margins, weak operating cash flow, and increasingly negative free cash flow. The balance sheet remains a partial strength because equity exceeds debt and leverage is manageable.

Income Statement

42Neutral

Balance Sheet

63Positive

Cash Flow

35Negative
Financial statement breakdown
BreakdownTTMMar 2025Mar 2024
Income Statement
Total Revenue857.19M1.87B1.64B
Gross Profit350.75M467.09M757.25M
EBITDA39.63M1.72M182.22M
Net Income-64.68M-170.74M6.17M
Balance Sheet
Total Assets4.20B4.24B4.19B
Cash, Cash Equivalents and Short-Term Investments53.75M48.23M51.98M
Total Debt1.12B1.15B1.05B
Total Liabilities1.75B1.89B1.62B
Stockholders Equity2.27B2.22B2.33B
Cash Flow
Free Cash Flow-115.70M-106.77M-178.78M
Operating Cash Flow201.52M8.53M267.52M
Investing Cash Flow-313.49M-115.30M-444.85M
Financing Cash Flow25.08M102.16M161.67M

Natural Capsules Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price144.70

Price Trends

50DMA163.09Negative
100DMA159.77Negative
200DMA158.19Negative

Market Momentum

MACD-3.15Negative
RSI44.41Neutral
STOCH67.39Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NATCAPSUQ, the sentiment is Negative. The current price of 144.70 is below the 20-day moving average (MA) of 145.27, below the 50-day MA of 163.09, and below the 200-day MA of 158.19, indicating a bearish trend. The MACD of -3.15 indicates Negative momentum. The RSI at 44.41 is Neutral, neither overbought nor oversold. The STOCH value of 67.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NATCAPSUQ.

Natural Capsules Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:NATCAPSUQ against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:PARIN:PAR73OutperformINR 1.41B10.87――9.40%34.12%
IN:BROOKSIN:BROOKS61NeutralINR 2.00B2.74――-14.88%431.30%
IN:BALPHARMAIN:BALPHARMA57NeutralINR 1.40B17.45―1.36%18.79%-2.58%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:ALPAIN:ALPA47NeutralINR 1.09B30.92――0.46%-83.31%
IN:NATCAPSUQIN:NATCAPSUQ44NeutralINR 1.51B-6.55――8.84%-285.42%
IN:NECLIFEIN:NECLIFE43NeutralINR 1.99B-3.02――-99.85%78.93%

* General Sector Average

Performance Comparison

-50%0%50%IN:NATCAPSUQIN:ALPAIN:BALPHARMAIN:BROOKSIN:NECLIFEIN:PARDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:NATCAPSUQ and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:NATCAPSUQNatural Capsules Limited144.70-39.05-21.25%
IN:ALPAAlpa Laboratories Limited51.60-26.88-34.25%
IN:BALPHARMABal Pharma Limited87.9511.1514.52%
IN:BROOKSBrooks Laboratories Limited67.90-35.60-34.40%
IN:NECLIFENectar Lifesciences Ltd.10.23-3.81-27.14%
IN:PARPar Drugs and Chemicals Limited114.8021.9723.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 29, 2026